Saturday, August 2, 2025

Latest

Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics.

In this interview with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we explore the company’s innovative approach to treating inflammatory heart conditions. Cardiol’s lead product, CardiolRx™, is an oral therapy targeting recurrent pericarditis and acute myocarditis – debilitating heart conditions that currently lack effective treatment options.

Elsley discusses their promising Phase 2 trial results presented at the American Heart Association, showing sustained pain reduction and decreased inflammation markers. He explains how their ultra-high-dose, pharmaceutically manufactured formulation differs from standard CBD products, and outlines key upcoming catalysts including Phase 2/3 trial results expected in early 2025 that could accelerate their path to market under FDA’s orphan drug designation.

READ: Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results


FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Why Gold’s Bull Run May Just Be Getting Started! | Peter Grandich

Tariffs Spark New Race for Critical Metals | Rob McEwen

Antimony Resources: The Bald Hill Project

Recommended

Tsunami Warnings Spread As Largest Quake Since 2011 Hits Russia

Northern Superior Intersects 1.75 g/t Gold Over 65.0 Metres At Philibert

Related News

Cardiol Therapeutics Announces US Listing

Cardiol Therapeutics (TSX: CRDL; OTCMKTS: CRTPF) announced this morning that it has qualified to trade...

Thursday, May 30, 2019, 09:43:44 AM

Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results

Cardiol Therapeutics (TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx,...
Tuesday, November 19, 2024, 08:19:00 AM

Cardiol Enters Into Supply Agreement With Shoppers Drug Mart

Cardiol Therapeutics Inc. (TSX: CRDL) has entered into a supplier agreement with Medical Cannabis by...

Wednesday, March 18, 2020, 03:27:03 PM

The Deep Dive Initiates Coverage on Cardiol Therapeutics

With a heavy focus on cannabinoids, Cardiol Therapeutics (TSX: CRDL) is not your typical cannabis...

Monday, April 29, 2019, 07:15:29 AM

Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members

Cardiol Therapeutics (TSX: CRDL) has seen a series of insider buys made in recent days,...
Friday, December 27, 2024, 09:52:00 AM